FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2551398029> ?p ?o ?g. }

• W2551398029 abstract "Doravirine is a novel, potent nonnucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of patients with human immunodeficiency virus type 1 (HIV-1) infection that demonstrates a high genetic barrier to resistance and that has been well tolerated in studies to date. Doravirine is a candidate for patients switching from less-well-tolerated NNRTIs, such as efavirenz. While doravirine is a cytochrome P450 3A4 (CYP3A4) substrate, efavirenz induces CYP3A4; therefore, the pharmacokinetics of both drugs following a switch from efavirenz to doravirine were assessed. This was a 3-period, fixed-sequence, open-label study. Healthy adults were dosed with doravirine at 100 mg for 5 days once daily (QD) (period 1). Following a 7-day washout, efavirenz was administered at 600 mg QD for 14 days (period 2). Subsequently, doravirine was administered at 100 mg QD for 14 days (period 3). Blood samples were collected for pharmacokinetic analyses. Twenty healthy subjects were enrolled, and 17 completed the study. One day after efavirenz cessation, the doravirine area under the concentration-time curve from predosing to 24 h postdosing (AUC0-24), maximum observed plasma concentration (Cmax), and observed plasma concentration at 24 h postdosing (C24) were reduced by 62%, 35%, and 85%, respectively, compared with the values with no efavirenz pretreatment. These decreases recovered to 32%, 14%, and 50% for AUC0-24, Cmax, and C24, respectively, by day 14 after efavirenz cessation. The doravirine C24 reached projected therapeutic trough concentrations, based on in vitro efficacy, on day 2 following efavirenz cessation. Geometric mean efavirenz concentrations were 3,180 ng/ml on day 1 and 95.7 ng/ml on day 15, and efavirenz was present at therapeutic concentrations (>1,000 ng/ml) until day 4. Though doravirine exposure was transiently decreased following efavirenz treatment cessation, dose adjustment may not be necessary to maintain therapeutic concentrations of at least one drug during switching in a virologically suppressed population." @default.
• W2551398029 created "2016-11-30" @default.
• W2551398029 creator A5012406150 @default.
• W2551398029 creator A5012941009 @default.
• W2551398029 creator A5013066371 @default.
• W2551398029 creator A5026265919 @default.
• W2551398029 creator A5041695667 @default.
• W2551398029 creator A5044812776 @default.
• W2551398029 creator A5049811881 @default.
• W2551398029 creator A5070094735 @default.
• W2551398029 creator A5074309174 @default.
• W2551398029 creator A5087795618 @default.
• W2551398029 date "2017-02-01" @default.
• W2551398029 modified "2023-10-16" @default.
• W2551398029 title "Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects" @default.
• W2551398029 cites W1988831468 @default.
• W2551398029 cites W1994500331 @default.
• W2551398029 cites W1998690882 @default.
• W2551398029 cites W2000929966 @default.
• W2551398029 cites W2040200721 @default.
• W2551398029 cites W2071086973 @default.
• W2551398029 cites W2077754502 @default.
• W2551398029 cites W2082257800 @default.
• W2551398029 cites W2106737113 @default.
• W2551398029 cites W2146591007 @default.
• W2551398029 cites W2151768713 @default.
• W2551398029 cites W2256825639 @default.
• W2551398029 cites W2327696366 @default.
• W2551398029 cites W2390017674 @default.
• W2551398029 cites W2416139320 @default.
• W2551398029 doi "https://doi.org/10.1128/aac.01757-16" @default.
• W2551398029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5278744" @default.
• W2551398029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27872069" @default.
• W2551398029 hasPublicationYear "2017" @default.
• W2551398029 type Work @default.
• W2551398029 sameAs 2551398029 @default.
• W2551398029 citedByCount "21" @default.
• W2551398029 countsByYear W25513980292016 @default.
• W2551398029 countsByYear W25513980292017 @default.
• W2551398029 countsByYear W25513980292018 @default.
• W2551398029 countsByYear W25513980292019 @default.
• W2551398029 countsByYear W25513980292020 @default.
• W2551398029 countsByYear W25513980292022 @default.
• W2551398029 countsByYear W25513980292023 @default.
• W2551398029 crossrefType "journal-article" @default.
• W2551398029 hasAuthorship W2551398029A5012406150 @default.
• W2551398029 hasAuthorship W2551398029A5012941009 @default.
• W2551398029 hasAuthorship W2551398029A5013066371 @default.
• W2551398029 hasAuthorship W2551398029A5026265919 @default.
• W2551398029 hasAuthorship W2551398029A5041695667 @default.
• W2551398029 hasAuthorship W2551398029A5044812776 @default.
• W2551398029 hasAuthorship W2551398029A5049811881 @default.
• W2551398029 hasAuthorship W2551398029A5070094735 @default.
• W2551398029 hasAuthorship W2551398029A5074309174 @default.
• W2551398029 hasAuthorship W2551398029A5087795618 @default.
• W2551398029 hasBestOaLocation W25513980291 @default.
• W2551398029 hasConcept C109650736 @default.
• W2551398029 hasConcept C112705442 @default.
• W2551398029 hasConcept C126322002 @default.
• W2551398029 hasConcept C142462285 @default.
• W2551398029 hasConcept C159047783 @default.
• W2551398029 hasConcept C185592680 @default.
• W2551398029 hasConcept C22979827 @default.
• W2551398029 hasConcept C2776452011 @default.
• W2551398029 hasConcept C2777351918 @default.
• W2551398029 hasConcept C2780727368 @default.
• W2551398029 hasConcept C2781432083 @default.
• W2551398029 hasConcept C2910800852 @default.
• W2551398029 hasConcept C2993143319 @default.
• W2551398029 hasConcept C3013748606 @default.
• W2551398029 hasConcept C526171541 @default.
• W2551398029 hasConcept C62231903 @default.
• W2551398029 hasConcept C71924100 @default.
• W2551398029 hasConcept C97320921 @default.
• W2551398029 hasConcept C98274493 @default.
• W2551398029 hasConceptScore W2551398029C109650736 @default.
• W2551398029 hasConceptScore W2551398029C112705442 @default.
• W2551398029 hasConceptScore W2551398029C126322002 @default.
• W2551398029 hasConceptScore W2551398029C142462285 @default.
• W2551398029 hasConceptScore W2551398029C159047783 @default.
• W2551398029 hasConceptScore W2551398029C185592680 @default.
• W2551398029 hasConceptScore W2551398029C22979827 @default.
• W2551398029 hasConceptScore W2551398029C2776452011 @default.
• W2551398029 hasConceptScore W2551398029C2777351918 @default.
• W2551398029 hasConceptScore W2551398029C2780727368 @default.
• W2551398029 hasConceptScore W2551398029C2781432083 @default.
• W2551398029 hasConceptScore W2551398029C2910800852 @default.
• W2551398029 hasConceptScore W2551398029C2993143319 @default.
• W2551398029 hasConceptScore W2551398029C3013748606 @default.
• W2551398029 hasConceptScore W2551398029C526171541 @default.
• W2551398029 hasConceptScore W2551398029C62231903 @default.
• W2551398029 hasConceptScore W2551398029C71924100 @default.
• W2551398029 hasConceptScore W2551398029C97320921 @default.
• W2551398029 hasConceptScore W2551398029C98274493 @default.
• W2551398029 hasFunder F4320307776 @default.
• W2551398029 hasIssue "2" @default.
• W2551398029 hasLocation W25513980291 @default.
• W2551398029 hasLocation W25513980292 @default.
• W2551398029 hasLocation W25513980293 @default.
• W2551398029 hasLocation W25513980294 @default.

• next